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(brachytherapy has been taken care of
by the Centre of Oncology in Cracow).
The QC- recommendations for simula-
tors and CT-scanners are in preparation.
Training of physicists and radiotherapists
(including the participants from other
East European countries) in order to
adhere to the increasing complexity of
modern radiotherapy procedures.
Trainings are performed individually or in
a form of courses. This activity follows
the recommendations of the Euroatom
Directive 97/43 on health protection of
individuals against the dangers of
ionizing radiation in relation to medical
exposure.
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Experimental data on cellular survival in
vitro often serve as a radiobiological basis
for modeling and interpreting the clinical
results of "classical" cancer radiotherapy,
using external photon and electron beams.
Since the radiobiological effectiveness
(RBE) of such beams is 1, the isodose
distribution, the basis for optimizing the
radiotherapy planning procedure, could
readily be interpreted as the distribution of
surviving cells in the tumour region, if a
suitable radiobiological model were
available. In the case of heavy-ion beam
radiotherapy where various techniques are
used to spread the Bragg peak over the
tumour volume, RBE is known to vary
widely along·the depth of the beam, and to
depend on many parameters, such as the
physical characteristics of the ion beam
(particle energy-fluence depth distribution,
ion charge, dose or fluence of initial
particles) and the radiobiological descrip-
tors of tumour and healthy tissue cell lines
(characterized, e.g., by in vitro survival
Rep. Praet. Oneol. Radiother. 8 (S2) 2003
curves and appropriate RBE-LET depen-
dences). To clinically evaluate results of
heavy-ion radiotherapy, typically, a "clinical
RBE" value is sought - a single factor by
which the physical dose of the heavy ions
should be multiplied to equate the clinical
effect of the "classical" (Le. photon or
electron) and heavy ion beam modalities,
in a similar clinical situation. The cellular
track structure theory developed by Katz
and co-workers, a four-parameter analy-
tical model, has been extremely successful
in quantitatively describing and predicting
RBE for cellular survival in vitro after
heavy ion bombardment, whereby RBE is
referred to a beam of Co-GO gamma rays.
Survival curves after a dose from a beam
of heavy ions (specified by the charge,
energy and fluence of these ions) can be
calculated, once the four parameters have
been simUltaneously fitted to a set of
experimentally measured cellular survival
curves. While the basic track structure
calculation concerns "track-segment" irra-
diation, the model provides for mixed-field
irradiation along the beam depth, thus cell
survival-beam depth dependences can be
readily calculated for realistic treatment
conditions, as a function of initial particle
fluence (representing entrance dose), say,
at the patient's skin. Thus, rather than
multiply the local dose from heavy ions by
an appropriate value of RBE to arrive at
"iso-biological dose" distributions, iso-
survival distributions after "conventional"
treatment (represented in the model by a
Co-GO beam) and after treatment with
beams of heavy charged particles, may be
compared. This approach and its possible
advantages against the usual comparison
of "physical dose*RBE = biological dose"
distributions, will be discussed.
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